Regulatory Lilly wins new FDA approval for eczema drug Ebglyss PharmaphorumLilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.Immunology & InflammationRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum Lilly’s Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drugNext: Aquipta recommended by NICE for acute migraine treatment Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
